Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

Several other equities research analysts also recently commented on CNTX. Jones Trading started coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price on the stock. HC Wainwright lifted their price target on shares of Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Thursday, November 6th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Context Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Context Therapeutics Trading Down 5.3%

Shares of CNTX opened at $2.30 on Monday. The stock has a market cap of $211.32 million, a PE ratio of -9.58 and a beta of 1.93. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $2.85. The stock has a 50 day simple moving average of $1.65 and a 200-day simple moving average of $1.24.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Marshall Wace LLP raised its position in shares of Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after acquiring an additional 2,557,448 shares during the last quarter. State Street Corp increased its position in Context Therapeutics by 8.5% in the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares during the period. Renaissance Technologies LLC increased its position in Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after purchasing an additional 188,202 shares during the period. Vanguard Group Inc. raised its holdings in Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Context Therapeutics in the 3rd quarter valued at about $100,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.